Results 211 to 220 of about 110,433 (337)

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Neuroplasticity mechanisms of NDBIs in autism: a review from brain connectivity to behavioral improvement. [PDF]

Eur J Med Res
Yan P, Zhu X, Tao Q, Shao X.
europepmc   +1 more source

Electroacupuncture Modulation of the Shh Signaling Pathway Regulates Neuroplasticity to Improve Anxiety-Like Behavior in Mcao Rats

Siyang Yan, Zihong Shen, Guolei Chen, Ludan Liang, Chang Liu, Xingui Wu   +5 more
openalex   +1 more source

The Role of Emotion, Vision and Touch in Movement Learning Neuroplasticity and the Mirror Neuron System [PDF]

, 2015
Jeanne Masterson
openalex   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Neuroplasticity, Cognition, and Creativity – Interdisciplinary Perspectives

Mirela Ștefănescu, Aurelian Bălăiță, Ligia Fărcășel   +2 more
openalex   +2 more sources

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Physical and Emotional Interventions in Modulating Neuroplasticity: A Narrative Review of Recent Evidence. [PDF]

Cureus
Babu B, Mohideen Bawa F, Parvathy G, Gupta AR, Gill GS, Paredes AA, Seitaj A, Herbert D, Gupta M.   +8 more
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

Neurobiological rhythms in critical care: A commentary on intensive care unit music therapy efficacy and mechanism. [PDF]

World J Crit Care Med
Nagamine T.
europepmc   +1 more source